KFAS
AMRX icon

Keating Financial Advisory Services’s Amneal Pharmaceuticals AMRX Stock Holding History

Keating Financial Advisory Services’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59K Buy
265
+25
+10% +$343 ﹤0.01% 1595
2026
Q1 		$2.98K Buy
240
+170
+243% +$2.28K ﹤0.01% 1682
2025
Q4 		$882 Buy
+70
New +$801 ﹤0.01% 1842

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Keating Financial Advisory Services's AMRX Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Amneal Pharmaceuticals (AMRX) stake by 10% in Q2 2026, buying an estimated $343 and bringing the position to 265 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1595.

Keating Financial Advisory Services first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Keating Financial Advisory Services held 265 shares of Amneal Pharmaceuticals worth $4.59K as of Q2 2026.
  • Keating Financial Advisory Services bought 25 Amneal Pharmaceuticals shares in Q2 2026, an estimated $343.
  • Amneal Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1595 holding.
  • Keating Financial Advisory Services first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.